Twining Biotech announced that the cumulative deviation value of the closing price increase of the company's shares exceeded 30% for three consecutive trading days, which is an abnormal fluctuation in stock trading. In response to abnormal fluctuations in the company's stock, the company carried out a comprehensive self-inspection and carefully verified the company's controlling shareholders and actual controllers on relevant matters through telephone calls and inquiries. There were no major changes in the company's daily business conditions and internal and external production and operation environment compared to before the abnormal fluctuation.